Matt Wolf, Contract Pharmacal Corp.’s CEO reports, “Rx-to-OTC switches have fueled tremendous growth in the category, with products such as Ibuprofen, Loratadine, Cetirizine, and Omeprazole. In fact, industry forecasts call for nearly $10 billion in potential switches over the next five years, in branded sales. Science has generated an entire class of products that are safe and effective—and easily purchased without a prescription in any pharmacy.
Growth in Rx-to-OTC switches
Increased sales opportunities and expiring patents on prescription-only products are two of the drivers behind manufacturers switching from selling their products as prescription or Rx-only to over-the-counter offerings.
Feb 6, 2010
Machinery Basics
Annual Outlook Report: Sustainability
The road ahead for CPGs in 2025 and beyond—<i>Packaging World</i> editors review key findings from a survey of 88 brand owners, CPG, and FMCG readers.
Download Now
Is your palletizing solution leaving money on the floor?
Discover which palletizing technology—robotic, conventional, or hybrid—will maximize your packaging line efficiency while minimizing long-term costs in this comprehensive analysis.
Read More